Form 13-F position report

CARDIOL THERAPEUTICS INC

Reported by Tejara Capital Ltd

CRDL CUSIP 14161Y200 Manager CIK 0001879713

Reported 5,113,822 shares, down 16,300 (0.3%) from the prior quarter.

Reported value -21.7%; share count -0.3% vs. the prior quarter.

Reduced
% of reported 13F value 2.23% This manager · Q2 2026
Shares 5,113,822 Quarter-end amount reported
Reported value $5,420,651 Fair value at quarter end
Consecutive quarters held 15 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 224719
2023-03-31 214717
2023-06-30 442384
2023-09-30 577684
2023-12-31 941581
2024-03-31 2976382
2024-06-30 3478931
2024-09-30 3507115
2024-12-31 3987759
2025-03-31 3098501
2025-06-30 4441514
2025-09-30 2814231
2025-12-31 4893110
2026-03-31 6925665
2026-06-30 5420651

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for CARDIOL THERAPEUTICS INC held by Tejara Capital Ltd.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 5,113,822 -16,300 (-0.3%) 2.23% $5,420,651 2026-08-11
Q1 2026 Unchanged 5,130,122 0 (0.0%) 2.28% $6,925,665 2026-05-12
Q4 2025 Added 5,130,122 +2,500,000 (95.1%) 1.15% $4,893,110 2026-02-05
Q3 2025 Reduced 2,630,122 -635,697 (-19.5%) 1.47% $2,814,231 2025-11-04
Q2 2025 Added 3,265,819 +70,829 (2.2%) 2.06% $4,441,514 2025-08-13
Q1 2025 Added 3,194,990 +79,553 (2.6%) 1.2% $3,098,501 2025-05-13
Q4 2024 Added 3,115,437 +1,344,167 (75.9%) 2.61% $3,987,759 2025-02-10
Q3 2024 Added 1,771,270 +49,027 (2.8%) 1.67% $3,507,115 2024-11-13
Q2 2024 Added 1,722,243 +77,833 (4.7%) 1.26% $3,478,931 2024-08-14
Q1 2024 Added 1,644,410 +527,734 (47.3%) 1.09% $2,976,382 2024-05-14
Q4 2023 Added 1,116,676 +471,219 (73.0%) 0.39% $941,581 2024-02-12
Q3 2023 Added 645,457 +148,396 (29.9%) 0.33% $577,684 2023-11-13
Q2 2023 Added 497,061 +56,435 (12.8%) 0.22% $442,384 2023-08-11
Q1 2023 Unchanged 440,626 0 (0.0%) 0.11% $214,717 2023-05-12
Q4 2022 New 440,626 +440,626 (0.0%) 0.13% $224,719 2023-02-13

Who else reported the position

58 managers reported CARDIOL THERAPEUTICS INC for Q2 2026.

Managers reporting CARDIOL THERAPEUTICS INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MMCAP International Inc SPC Added 15,598,560 +246,243 1.4% $16,534,474 19 qtrs
Tejara Capital Ltd This report Reduced 5,113,822 -16,300 2.23% $5,420,651 15 qtrs
Ikarian Capital LLC Added 3,325,000 +600,000 0.38% $3,524,500 2 qtrs
BOOTHBAY FUND MANAGEMENT LLC Added 975,721 +180,840 0.01% $1,034,264 2 qtrs
CITADEL ADVISORS LLC Reduced 796,529 -23,375 < 0.01% $844,320 4 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 772,837 +543,031 < 0.01% $819,207 2 qtrs
TWO SIGMA INVESTMENTS LP Added 746,937 +212,726 < 0.01% $791,753 4 qtrs
INTEGRITY ALLIANCE LLC Reduced 388,492 -76,533 0.01% $411,802 3 qtrs
MORGAN STANLEY Added 355,030 +104,609 < 0.01% $376,332 9 qtrs
The Goldman Sachs Group Inc Added 333,900 +1,500 < 0.01% $353,934 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 11, 2026
Filing type
13F-HR
Position type
COM CL A

Voting authority reported

Sole
5,113,822
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.